Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation

This is a single-center, Phase II randomized study of MM patients comparing 16 weeks of DLC access versus quasi-usual care (quasi-usual because both arms will receive generic wellness-related electronic handouts alongside requests for patient-reported outcome (PRO) assessments).

Primary Objective:

To evaluate DLC's impact on B/Z drug usage (excluding lorazepam prescribed for chemotherapy-induced nausea/vomiting, or CINV)

Secondary Objectives:

1. To evaluate DLC's impact on patient-reported general quality of life every 1-2 weeks
2. To evaluate DLC's impact on patient-reported psychosocial distress every 1-2 weeks
3. To evaluate DLC's impact on patient-reported insomnia every 1-2 weeks

Exploratory Objectives:

1. To explore DLC's impact on rates of communications between patients and their treatment teams
2. To explore DLC's impact on clinical outcomes

Participants may continue study treatment (DLC platform access) for 16 weeks from the time of initiating treatment. Participants will not be contacted by the DLC platform vendor after this point. Patients will be followed up at Day +101 after SCT, corresponding to approximately 3 months after SCT.

• Pack Health's Digital Life Coaching (DLC) (Behavioral), also known as DLC: Pack Health smartphone-based DLC platform
• Electronic Handouts (Other): Generic wellness-related electronic handouts

Primary outcomes

• Comparison of patients with >=1 benzodiazepine and Z-class (B/Z) prescriptions (versus < 1 B/Z prescriptions) [Up to 6 months]: Proportions of patients with >=1 B/Z prescription versus <1 B/Z prescriptions will be compared between arms using chi-square analyses. Participants will be stratified on B/Z usage over time into 3 groups arms based on B/Z-naïve status (i.e., no B/Z usage at time of study enrollment), baseline psychosocial distress, defined as an National Comprehensive Caner Network (NCCN) Distress Thermometer (DT) score of 4 or higher, and baseline insomnia, defined as a Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance short form (SF) 4 item (4a) standardized score of 57 or higher.
• Estimate change in B/Z usage [Up to 6 months]: Estimations or differences in changes over time by study group will be performed via a post-estimation test using one-sided t-tests at each assessment. To control the family wise error rate at alpha level of 0.05, the Bonferroni method will be used.
• Number of participants with a missing Patient Reported Outcome Measurement Information System (PROMIS) Global Health (GH) assessment [Up to 6 months]: Sensitivity analyses for missing data will be performed on participants with missing PROMIS Global Health assessments
• Number of participants with a missing NCCN Distress Thermometer (DT) assessment [Up to 6 months]: Sensitivity analyses for missing data will be performed on participants with missing NCCN DT Assessments
• Number of participants with a missing PROMIS Sleep Disturbance SF-4a inventory [Up to 6 months]: Sensitivity analyses for missing data will be performed on participants with missing PROMIS Sleep Disturbance SF-4a inventories.

Secondary outcomes

• Change in PROMIS Global Health (GH) Scale Scores [Up to 6 months]: This 10-item inventory is part of the PROMIS series to assess quality of life (QOL) with item scores ranging from 1 to 5. Raw PROMIS scores will be transformed to T-score metrics to reflect a population mean of 50 and a standard deviation of 10. Among cancer patients, a T-score change of 5 points on any PROMIS inventory is generally considered to be clinically meaningful
• Change in NCCN Distress Thermometer (DT) Scores [Up to 6 months]: This single-item inventory uses an analog graphic to allow patients to assess their overall distress with a score range of 0 (no distress) to 10 (extreme distress). A score of 4 or higher to differentiate clinically significant distress.
• Change in PROMIS 4-item Sleep Disturbance Short Form (SF-4a) Scores [Up to 6 months]: The PROMIS Sleep Disturbance SF-4a inventory will be used to assess quality of sleep, with item scores ranging from 1 to 5. Raw PROMIS scores will subsequently be transformed to T-score metrics to reflect a population mean of 50 and standard deviation of 10. As validated in a previous study of cancer patients, a PROMIS Sleep Disturbance score of 57 or higher will be defined as insomnia.

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Confirmed diagnosis of one of the following (all referred to as multiple myeloma (MM) for the purposes of this protocol):

  * Multiple myeloma (ICD-10 code: C90.0)
  * Extramedullary plasmacytoma (ICD-10 code: C90.2)
* Planned receipt of autologous stem cell transplantation (SCT) at University of California, San Francisco (UCSF)

  * Patients undergoing outpatient SCT will be eligible
  * Patients who received chemomobilization will be eligible
* Ability to understand a written informed consent form (ICF) document, and the willingness to sign the ICF document

Exclusion Criteria:

* Age < 18 years
* SCT as salvage therapy
* Patient-assessed lack of sufficient English proficiency
* Lack of ownership of a personal smartphone

• Rahul Banerjee, MD, Principal investigator, University of California, San Francisco